ArticleCell2016
Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.
Abstract read
In one paragraph
Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers.
0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed.
- Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.Science (New York, N.Y.) · 2025Trial
- Vaccination induces HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2022Trial
- Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.The Journal of infectious diseases · 2019Trial
- Overcoming immunogenic gaps in malaria subunit vaccines by broadening CSP regions targeted.The Journal of experimental medicine · 2026Article
- Article
- Rapid boosting increases germinal center responses to sequential vaccines.Nature immunology · 2026Article
- VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.Research square · 2026Article
- Maturation of HIV-1 neutralizing antibodies in a germinal center conditional expression mouse model.PLoS pathogens · 2026Article
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.Immunity · 2026Article
- Deep learning-enabled scaffolding of spatial arrays of PfCSP epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).medRxiv : the preprint server for health sciences · 2026Article
- Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization.Science immunology · 2026Article
- DNA origami vaccines program antigen-focused germinal centers.Science (New York, N.Y.) · 2026Article
- Functional Convergence of Genetically Diverse B-Cell Receptors in Simian-HIV Infected Rhesus Macaques.bioRxiv : the preprint server for biology · 2026Article
- Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors.Vaccines · 2026Article
- The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials.Current HIV research · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.bioRxiv : the preprint server for biology · 2025Article
- Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models.Science immunology · 2025Article
- Simultaneous induction of multiple classes of broadly neutralizing antibody precursors by combination germline-targeting immunization in nonhuman primates.Science immunology · 2025Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
40 authors.
Ming TianProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Cheng ChengVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Xuejun ChenVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Hongying DuanVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Hwei-Ling ChengProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Mai DaoProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Zizhang ShengDepartment of Biochemistry and Molecular Biophysics and Department of Systems Biology, Columbia University, New York, NY 10032, USA.
Michael KimbleProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Sherry LinProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Stephen D SchmidtVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Zhou DuProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
M Gordon JoyceVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Yiwei ChenProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Brandon J DeKoskyVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Yimin ChenProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Erica NormandinVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Elizabeth CantorProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Rita E ChenVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Yi ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Wei ShiVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Wing-Pui KongVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Misook ChoeVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Amy R HenryVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Farida LabouneVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Ivelin S GeorgievVanderbilt Vaccine Center, Vanderbilt University, Nashville, TN 37232, USA.
Pei-Yi HuangProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Suvi JainProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Andrew T McGuireFred Hutchinson Cancer Research Center, Seattle, WA 02129, USA.
Eric GeorgesonDepartment of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Sergey MenisDepartment of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
William R SchiefDepartment of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Cambridge, MA 02129, USA; Harvard University, Cambridge, MA 02129, USA.
Leonidas StamatatosFred Hutchinson Cancer Research Center, Seattle, WA 02129, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Lawrence ShapiroVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA; Department of Biochemistry and Molecular Biophysics and Department of Systems Biology, Columbia University, New York, NY 10032, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. Electronic address: jmascola@mail.nih.gov.
Frederick W AltProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: alt@enders.tch.harvard.edu.
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MSupport Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5MPreclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class AnU19AI109632 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2014 to 2020
$25.1MNeutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6MNon-Human PrimatesP01AI104722 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2014 to 2018
$14.6MMechanisms that Control IgH Variable Region Exon AssemblyR01AI020047 · NIAID · IMMUNE DISEASE INSTITUTE, INC. · PI ALT, FREDERICK W. · 1985 to 2025
$14.1MStructure/function studies of immunogen recognition by anti-HIV antibody b12P01AI094419 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2011 to 2015
$10.6MPreclinical Evaluation Of Neutralizing Antibodies Elicited by HIV-1 ImmunogensZIAAI005012 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$7.1MDesigning and optimizing candidate HIV vaccines and boosting protocolsR01AI128836 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2017 to 2021
$4.8MMechanisms that Regulate Antibody Class Switch Recombination and Somatic HypermutationR37AI077595 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Frederick W. Alt · 2019 to 2026
$4.6MMolecular Mechanisms of Class Switch RecombinationR01AI077595 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI ALT, FREDERICK W. · 2009 to 2018
$4.3MASSEMBLY AND EXPRESSION OF IG VARIBLE REGION GENESR37AI020047 · NIAID · IMMUNE DISEASE INSTITUTE, INC. · PI ALT, FREDERICK W · 1991 to 2000
$323kHoward Hughes Medical InstituteNIAID NIH HHS F31 AI117920NIAID NIH HHS P01 AI094419NIAID NIH HHS P01 AI104722NIAID NIH HHS R01 AI020047NIAID NIH HHS R01 AI077595NIAID NIH HHS R01 AI128836NIAID NIH HHS R37 AI020047NIAID NIH HHS R37 AI077595NIAID NIH HHS U19 AI109632NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI100663
Abstract
The design of immunogens that elicit broadly reactive neutralizing antibodies (bnAbs) has been a major obstacle to HIV-1 vaccine development. One approach to assess potential immunogens is to use mice expressing precursors of human bnAbs as vaccination models. The bnAbs of the VRC01-class derive from the IGHV1-2 immunoglobulin heavy chain and neutralize a wide spectrum of HIV-1 strains via targeting the CD4 binding site of the envelope glycoprotein gp120. We now describe a mouse vaccination model that allows a germline human IGHV1-2(∗)02 segment to undergo normal V(D)J recombination and, thereby, leads to the generation of peripheral B cells that express a highly diverse repertoire of VRC01-related receptors. When sequentially immunized with modified gp120 glycoproteins designed to engage VRC01 germline and intermediate antibodies, IGHV1-2(∗)02-rearranging mice, which also express a VRC01-antibody precursor light chain, can support the affinity maturation of VRC01 precursor antibodies into HIV-neutralizing antibody lineages.
Indexed as
ImmunizationAnimalsAntibodies, MonoclonalAntibodies, NeutralizingB-LymphocytesBroadly Neutralizing AntibodiesCell LineDisease Models, AnimalGene Expression RegulationHIV-1HIV AntibodiesImmunoglobulin Heavy ChainsInhibitory Concentration 50MicePrecursor Cells, B-LymphoidSequence DeletionAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin Heavy ChainsVRC01 monoclonal antibody
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.